ArticleCureus2026
Mesenchymal Tumor of the Hand Causing Tumor-Induced Osteomalacia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-induced osteomalacia (TIO) is an ultra-rare paraneoplastic syndrome caused by excessive secretion of fibroblast growth factor 23 (FGF23) from phosphaturic mesenchymal tumors, leading to renal phosphate wasting, hypophosphatemia, and osteomalacia. Diagnosis is frequently delayed due to nonspecific symptoms and the difficulty of localizing small, often indolent tumors. We report a 55-year-old male patient who presented with a 16-month history of progressive muscle weakness, chronic bone pain, and multiple bilateral metatarsal fractures. Laboratory evaluation demonstrated profound hypophosphatemia (1.6 mg/dL), markedly elevated FGF23 levels (455 RU/mL), and renal phosphate wasting (tubular reabsorption of phosphate at 35%, tubular maximum phosphate reabsorption per glomerular filtration rate (TmP/GFR) at 1.04 mg/dL). Initial fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) was non-localizing. Following referral to a tertiary center, specialized re-interpretation of imaging identified faint focal uptake in the right third metacarpal. This finding was confirmed with technetium-99m sestamibi scintigraphy and magnetic resonance imaging, which revealed a 1.9 × 1.8 × 1.2 cm soft-tissue mass within the palmar tissues. Surgical excision was performed, and histopathology confirmed a phosphaturic mesenchymal tumor with positive FGF23 in situ hybridization. Postoperatively, serum phosphorus levels normalized, confirming biochemical cure. This case underscores the diagnostic challenges associated with TIO, particularly tumor localization, and highlights the critical role of expert imaging interpretation. Complete surgical resection remains the definitive treatment, resulting in rapid biochemical normalization and clinical improvement. The unusual hand location and initially non-localizing imaging emphasize the importance of a systematic, multidisciplinary approach in the evaluation and management of this rare but highly treatable condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.